JAK2/mTOR inhibition fails to prevent acute GVHD despite reduced Th1/Th17 cells: final phase 2 trial results.
Pidala J, Holtan SG, Walton K, Kim J, Cao B, Elmariah H, Mishra A, Bejanyan N, Nishihori T, Khimani F, Perez L, Faramand RG, Davila ML, McSain S, Pleskow J, Baron J, Anasetti C, Moran Segura C, Weisdorf DJ, Blazar BR, Miller JS, Bachanova V, El Jurdi N, Betts BC.
Pidala J, et al. Among authors: miller js.
Blood. 2024 Nov 28;144(22):2295-2307. doi: 10.1182/blood.2024024789.
Blood. 2024.
PMID: 39046783
Free article.
Clinical Trial.